JEFFREY WHEELER: Open Payments
NPI 1699942987 · ROOSEVELT, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$541 in 28 payments from 10 companies in 2025. Trend: 2023 $323 · 2024 $408 · 2025 $541
Food & beverage: $541
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $160 |
| Xeris Pharmaceuticals, Inc. | 5 | $105 |
| ABBVIE INC. | 4 | $74 |
| Corcept Therapeutics | 4 | $69 |
| PFIZER INC. | 2 | $35 |
| Janssen Biotech, Inc. | 2 | $32 |
| Verona Pharma, Inc. | 1 | $26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $9 |
Products named: AIRSUPRA, GVOKE HYPOPEN, Korlym, VRAYLAR, NURTEC ODT, TREMFYA, Ohtuvayre, FARXIGA.
Industry payments across UT — which companies pay providers there.
